Abstract: Commercially feasible methods for lyophobic precipitation of liquid-dispersed or dissolved material (e.g., medicaments) are provided wherein a plurality of individual, open containers (22) each containing a quantity (84) of a solution or dispersion are treated within a common pressurizable chamber (12). In this process, desired near-supercritical or supercritical temperature and pressure conditions are established for a selected antisolvent gas such as carbon dioxide, and an ultrasonic device (14) is actuated to generate high energy ultrasonic waves in the chamber (12). This leads to intense mixing of the antisolvent with the liquid solution or dispersion within the containers (22), with consequent solvent removal and material precipitation.

Abstract: Disclosed are methods and compositions for the treatment of a wide array of cancers and tumors. In illustrative embodiments, diindolylmethanes, C-substituted diindolylmethanes, and analogs thereof have been described, which when administered either alone, or in combination with other anti-cancer or anti-tumorigenic compounds, provide new therapies for the treatment of cancer.

Abstract: The invention relates to a process for the preparation of ionic liquids of general formula (cation)(R?—O—SO3). The process includes the step of treating the compound of formula (cation)(R—O—SO3) with an alcohol, or mixture of different alcohols, of the formula R?—OH optionally in the presence of a catalyst to form the desired ionic liquid and the by-product R—OH, which is optionally removed during the reaction or after completion of the reaction. The compound of formula (cation)(R—O—SO3) can be prepared by alkylating a tertiary or aromatic amine with a dialkylsulfate.

Abstract: The present invention provides a laser drilling system for drilling holes or cavities in a solid, in particular a solid dosage form. The system includes a loading zone, firing zone, inspection zone and delivery zone. The system also includes optional components such as a process validation system, solids detector, color detector, solids rejection/repositioning means, accepted products receptacle, rejected products receptacle and/or solids inspection system. Operation of the laser device in the firing zone and of other optional equipment is synchronized with movement of a continuous solids indexer by way of an electronic synchronizer. A solids handling system includes an optional fill level detector that directly or indirectly controls solids loading means that fills a solids reservoir. The system can be run continuously, semicontinuously or batchwise.

Abstract: A system and method for calculating, collecting and/or disbursing one or more third party payments owed to one or more third parties resulting from one or more electronic transactions occurring over a wide area network (WAN) between a customer and a merchant. The present system includes a merchant node, third party payment processing node, financial network, and third party payment receiving node. A consumer conducts a transaction at a merchant node; whereby, a third party may or may not be due a payment. The third party payment processing node determines whether such payment is due, calculates the amount of the third party payment, and/or authorizes payment of the third party payment. The financial network then handles payment of the amount(s) due to the third party, the amount(s) due to the merchant and the amount(s) owed by the customer.

Abstract: This invention relates to a process for removing polarizable impurities from hydrocarbons and mixtures of hydrocarbons using ionic liquids as an extraction medium. By way of extraction, the degree of contamination of the hydrocarbon or mixture of hydrocarbons is reduced to a low or very low level. The specific ionic liquids are compounds of the Formula 1, which are organic salts that are liquid or can be melted to form a liquid and that can form at least a biphasic mixture with a hydrocarbon. The process is suitable for purifying a wide range of hydrocarbons under a wide range of process conditions.

Abstract: Low melting ionic compounds of the general formula (cation) (R?SO4) in which R? is a branched or linear, saturated or unsaturated, aliphatic or alicyclic functionalized or non-functionalized hydrocarbon chain with 3-36 carbon atoms are provided. These compounds can serve as ionic liquids, e.g. as solvents or solvent additives in chemical reactions, as extraction agents or as heat carriers. The compounds comprise a cation and anionic sulfate ester.

Abstract: Amino acid diamides in non ? position of formula (1), wherein R1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO2, OH, OCH3 alone or associated and R2 is selected from the group consisting of functional groups H, alkyl, halogen, NO2, OH, OCH3, which are useful as adjuvants for the administration of biological active agents, as well as pharmaceutical compositions containing these diamides of formula (1) and the use thereof for the manufacture of antithrombotic medications and for the manufacture of a medication for the treatment of a disease selected from amongst the group consisting of inflammation, cancer and allergy.

Abstract: A method for the extraction of pharmacologically active components from the oleander plant using supercritical carbon dioxide and combining the extraction with other isolation methods. The extraction is carried out using carbon dioxide at supercritical conditions, with or without the addition of a modifier. The isolated product is recovered in higher yield than with traditional hot water extraction.

Abstract: The invention provides a system and method for calculating, collecting and/or disbursing one or more third party payments owed to one or more third parties resulting from one or more electronic transactions occurring over a wide area network (WAN) between a customer and a merchant. The transaction concern one or more services and/or products provided by the merchant. The system and method require that the calculation of the amount owed to the third party occur at a WAN node that is different than and at a different locale than that of the merchant. By so doing, the merchant is not required to purchase and install equipment and/or software of the third party to which a payment is due. The present system includes a merchant node, third party payment processing node, financial network, and third party payment receiving node. A consumer conducts a transaction at a merchant node. As a result of the transaction, a third party may or may not be due a payment.

Abstract: A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder. This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.

Abstract: Low melting ionic compounds of the general formula (cation) (R?SO4) in which R? is a branched or linear, saturated or unsaturated, aliphatic or alicyclic functionalized or non-functionalized hydrocarbon chain with 3-36 carbon atoms are provided. These compounds can serve as ionic liquids, e.g. as solvents or solvent additives in chemical reactions, as extraction agents or as heat carriers. The compounds comprise a cation and anionic sulfate ester.

Abstract: Disclosed are methods and compositions for the treatment of a wide array of cancers and tumors. In illustrative embodiments, diindolylmethanes, C-substituted diindolylmethanes, and analogs thereof have been described, which when administered either alone, or in combination with other anti-cancer or anti-tumorigenic compounds, provide new therapies for the treatment of cancer.

Abstract: The present invention provides a dual release solid dosage form containing a first composition that releases a neuraminidase inhibitor, such as oseltamivir, zanamivir, or peramivir, in a controlled manner and a second composition that releases an H1 antagonist in a rapid and/or immediate manner. A wide range of H1 antagonist antihistamines, especially fexofenadine and loratadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. The device is useful for the treatment of respiratory congestion and other viral infection associated symptoms.

Abstract: The invention provides a bale handling apparatus capable of being used to lift and transport two similar bales in a substantially side-by-side manner. The apparatus includes at least two vertically and horizontally offset main spears. Each main spear is grouped with at least one vertically and/or horizontally offset stabilizer spear. By virtue of the offset design of the main spears, the apparatus can be used to load two bales sequentially by lifting a first bale and then lifting a second bale without unloading the first bale from the apparatus. The apparatus can also be used to load two bales simultaneously. The two bales can then be transported together to another location and unloaded from the apparatus sequentially or simultaneously.

Abstract: The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations.

Abstract: The present invention provides a disc player comprising one or more light sources that project a constant or pulsing light onto the upper portion of a disc being played by the disc player. If a constant light source is used, the a pulsing viewing port for the disc receptacle of the disc player is employed. The pulse frequency, pulse length, pulse period, pulse interval, pulse color, pulse intensity or a combination thereof of the light source or the pulse frequency, pulse length, pulse period, pulse interval, or light transmissivity of the one or more viewing ports can be synchronized with the rotation of the spindle or platen in the disc player, with the optical data stored, or with the rotation of an image precursor on the disc. When the disc is viewed through a viewing port while the disc is being played, a two-dimensional or three-dimensional discrete image is formed by the persistence of vision.

Abstract: The present invention relates to novel antagonists to a B1-bradykinin (B1-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B1 receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B1-BK receptors in these two models. B1-BK antagonists abolished the vasocontraction induced by B1-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels.

Abstract: An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether ?-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

Abstract: The present invention provides a simple and improved multi-layered osmotic device (1) that is capable of delivering a first active agent in an outer lamina (2) to one environment of use and a second active agent in the core (5) to another environment of use. Particular embodiments of the invention provide osmotic devices in which the first and second active agents are similar or dissimilar. An erodible polymer coat (3) between an internal semipermeable membrane (4) and a second active agent-containing external coat (2) comprises poly(vinylpyrrolidone)-(vinyl acetate) copolymer. This particular erodible polymer results in an improved multi-layered osmotic device possessing advantages over related devices known in the art. The active agent in the core (5) is delivered through a pore (6) containing an erodible plug (7). The osmotic device (1) can be coated by a final finish coat (8).